Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline

As it broadens the clinical ambitions for its small molecule oncology programs, Scorpion Therapeutics has secured $150 million in financial fuel.

The Boston-based biotech applies its drug-hunting platform to validated oncogenes to create small-molecule drug candidates against undruggable targets. The so-called “Precision Oncology 2.0” platform combines advances in genomic tools like CRISPR, medicinal chemistry and data capabilities such as chemical proteomics and supercomputing.